July 2011

When Robert A. Weinberg was a boy, he loved dissecting what was complicated and figuring out what made it work.

Amid growing cost pressures in the pharmaceutical industry, many small companies are playing an increasingly active role in drug development.

Intense research has resulted in JAK-STAT becoming one of the best-understood signal transduction cascades.

Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

Every decade during the past 50 years, treatment for multiple myeloma has taken a leap forward.

Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.

Which studies should influence how I manage my patients and what criteria should I use to make these decisions?

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

The field of immunotherapy is brimming with questions that researchers are working to answer, and many of those efforts were on display at the ASCO annual meeting.

Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.